# US 2026/0251655 A1 · Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0251655 A1
- Document ID: US20260251655A1
- Status: Published application
- Kind: A1
- Application number: 19/162,737
- Filed: 2024-03-18
- Published: 2026-08-27
- Earliest claimed: 2023-03-17
- Assignees: PAM Theragnostics GmbH
- Applicants: PAM Theragnostics GmbH
- Inventors: Andreas Bergmann
- Web page: https://patentgrep.com/patent/US20260251655A1

## CPC

- G01N 33/573: for enzymes or isoenzymes
- C07K 16/40: against enzymes
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- G01N 2333/90245: acting on paired donors with incorporation of molecular oxygen (1.14)
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- G01N 2800/2821: Alzheimer
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/7028: Cancer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention is directed to methods for determining the level of PAM and/or its isoforms and/or fragments thereof in a bodily fluid or a tissue sample using an assay, wherein said assay is comprising at least one binder that is directed to a conformational epitope of PAM, and its use for diagnostic purpose.

## Claims

### Claim 1

A method for determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or isoforms and/or fragments thereof in a sample of bodily fluid or a tissue using an assay, wherein said assay is comprising at least one binder that is directed to a conformational epitope of PAM.

### Claim 2 (depends on 1)

The method for determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or isoforms and/or fragments thereof in a sample of bodily fluid or a tissue according to claim 1, wherein said assay is comprising two binders that bind to two different regions of PAM, wherein each of the two binders is directed to a conformational epitope of PAM.

### Claim 3 (depends on 2)

The method for determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or isoforms and/or fragments thereof in a sample of bodily fluid or a tissue according to claim 2, wherein first binder of said two binders binds to a conformational epitope comprised within the PHM subunit of PAM (SEQ ID No. 7) and second binder of said two binders binds to a conformational epitope comprised within the PAL subunit of PAM (SEQ ID No. 8).

### Claim 4 (depends on 2, 3)

The method for determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or isoforms and/or fragments thereof in a sample of bodily fluid or a tissue according to claim 2 or 3, wherein each of said two binders is directed to an epitope comprised within the following sequences of PAM: SEQ ID No. 25 (PHM, amino acids 31-377 of SEQ ID No.1) and SEQ ID No. 8 (PAL, amino acids 495-817 of SEQ ID No.1) of human PAM.

### Claim 5 (depends on 1, 2, 3, 4)

The method for determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or isoforms and/or fragments thereof in a sample of bodily fluid or a tissue according to any of claims 1 to 4, wherein said conformational epitope is of at least 4 amino acids, preferably of at least 5 amino acids.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method for determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or isoforms and/or fragments thereof in a sample of bodily fluid or a tissue according to any of claims 1 to 5, wherein said binder does not bind to denatured PAM or denatured subunits of PAM (e.g. PAL or PHM).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method for determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or isoforms and/or fragments thereof in a sample of bodily fluid or a tissue according to claims 1 to 6, wherein said binder does not bind to denatured PAM or denatured subunits of PAM (e.g. PAL or PHM) using Western Blot techniques.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method for determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or isoforms and/or fragments thereof in a sample of bodily fluid or a tissue according to any of claims 1 to 7, wherein said binder that is directed to a conformational epitope of PAM binds to enzymatically active PAM or enzymatically active subunits of PAM (e.g. PAL or PHM) but not enzymatically inactive PAM or enzymatically inactive subunits of PAM (e.g. PAL or PHM).

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A method for determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or isoforms and/or fragments thereof in a sample of bodily fluid or a tissue according to any of claims 1 to 8, wherein said at least one binder is selected from the group consisting of antibody, antibody fragment or non-IgG scaffold.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method for determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or isoforms and/or fragments thereof in a sample of bodily fluid or tissue according to any of claims 1 to 9, wherein said at least one binder is produced using large fragment protein, full-length protein or DNA immunization techniques.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method for diagnosis or prognosis of a disease in a patient and/or predicting a risk of getting a disease or an adverse event in a patient and/or monitoring a disease or an adverse event in a patient by determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or its isoforms and/or fragments thereof in a sample of bodily fluid or a tissue of said patient according to any of claims 1 to 10,
wherein the disease in said patient is selected from the group comprising dementia, cardiovascular disorders, kidney diseases, cancer, inflammatory or infectious diseases and/or metabolic diseases,
wherein the adverse event is selected from the group comprising a cardiac event, a cardiovascular event, a cerebrovascular event, a cancer, diabetes, infections, serious infections, sepsis-like systemic infections, sepsis and death due to all causes.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method for diagnosis or prognosis of a disease in a patient and/or predicting a risk of getting a disease or an adverse event in a patient and/or monitoring a disease or adverse event in a patient by determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or its isoforms and/or fragments thereof in a sample of bodily fluid or a tissue of said patient according to any of claims 1 to 11, the method comprising the following steps:
determining the level of PAM and/or its isoforms and/or fragments thereof in a sample of bodily fluid or a tissue of said patient,
comparing said determined amount to a predetermined threshold,
wherein said patient is diagnosed as having a disease if said determined amount is below or above said predetermined threshold, or
wherein an outcome of a disease is prognosticated if said determined amount is below or above said predetermined threshold, or
wherein the risk of getting a disease or an adverse event is predicted in said patient if said determined amount is below or above said predetermined threshold, or
wherein a disease or an adverse event of said patient is monitored.

### Claim 13 (depends on 1, 12)

A method according to claims 1 and 12, wherein the level of PAM and/or its isoforms and/or fragments thereof is the total concentration of PAM and/or its isoforms and/or fragments thereof having at least 12 amino acids in a sample of bodily fluid or a tissue of said patient.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method according to any of claims 1 to 13, wherein the total concentration of PAM and/or its isoforms and/or fragments thereof having at least 12 amino acids is detected with an immunoassay.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method for diagnosis or prognosis of a disease in a patient and/or predicting a risk of getting a disease or adverse event in a patient and/or monitoring a disease or adverse event in a patient by determining the level of PAM and/or its isoforms and/or fragments thereof in a sample of bodily fluid or a tissue of said patient according to any of claims 1 to 14, wherein the PAM and/or its isoforms and/or fragments thereof is selected from the group comprising SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8 and SEQ ID No. 10.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method for diagnosis or prognosis of a disease in a patient and/or predicting a risk of getting a disease or adverse event in a patient and/or monitoring a disease or adverse event in a patient by determining the level of PAM and/or its isoforms and/or fragments thereof in a sample of bodily fluid or a tissue of said patient according to any of claims 1 to 15, wherein the risk of getting a disease of a patient is determined, wherein said patient is a healthy patient.

### Claim 17 (depends on 16)

A method according to claim 16, wherein said disease is selected from the group of Alzheimer's disease, colorectal cancer and pancreatic cancer.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A method for determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or isoforms and/or fragments thereof in a sample of bodily fluid or tissue according to any of claims 1 to 17, wherein said level is the level of active PAM.

### Claim 19

Use of antibodies for determining the level of PAM and/or its isoforms and/or fragments thereof, wherein said antibodies are directed to a conformational epitope comprised within the following sequences of PAM:PHM fragment (amino acids 31-377 of PAM) (SEQ ID No. 25) and/or PAL fragment (amino acids 495-817 of PAM) (SEQ ID No. 8).

### Claim 20 (depends on 19)

Use of antibodies for determining the level of PAM and/or its isoforms and/or fragments thereof according to claim 19, wherein said antibody does not bind to denatured PAM or denatured subunits of PAM (e.g. PAL or PHM).

### Claim 21 (depends on 19, 20)

Use of antibodies for determining the level of PAM and/or its isoforms and/or fragments thereof according to claims 19 and 20, wherein said antibody that is directed to a conformational epitope of PAM binds to enzymatically active PAM or enzymatically active subunits of PAM (e.g. PAL or PHM) but not to enzymatically inactive PAM or enzymatically inactive subunits of PAM (e.g. PAL or PHM).

### Claim 22

Kit for determining the level of PAM and/or its isoforms and/or fragments thereof, comprising one or more antibodies binding to PAM, which are directed to a conformational epitope comprised within the following sequences of PAM:PHM fragment (amino acids 31-377 of PAM) (SEQ ID No. 25) and/or PAL fragment (amino acids 495-817 of PAM) (SEQ ID No. 8).

### Claim 23 (depends on 22)

Kit for determining the level of PAM and/or its isoforms and/or fragments thereof, comprising one or more antibodies binding to PAM according to claim 22, wherein said antibody does not bind to denatured PAM or denatured subunits of PAM (e.g. PAL or PHM).

### Claim 24 (depends on 22, 23)

Kit for determining the level of PAM and/or its isoforms and/or fragments thereof, comprising one or more antibodies binding to PAM according to claims 22 and 23, wherein said antibody that is directed to a conformational epitope of PAM binds to enzymatically active PAM or enzymatically active subunits of PAM (e.g. PAL or PHM) but not to enzymatically inactive PAM or enzymatically inactive subunits of PAM (e.g. PAL or PHM).
